Apnimed

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Rznomics To Partner With Lilly On

Obstructive sleep apnea (OSA) is a therapeutic area with an entrenched therapy – continuous positive air pressure (CPAP) devices – but with the first Phase III data in hand for its combination pill AD

Lawrence Miller is not afraid of giants. The CEO of sleep apnea-focused Apnimed believes that even though Eli Lilly’s Zepbound (tirzepatide) recently won approval for treating moderate-to-severe obstr

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding